Overview

BRAF V600E-mutant and MSI-H Metastatic Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus Pembrolizumab Compared to Pembrolizumab Alone

Status:
Not yet recruiting

Trial end date:
2027-02-10

Target enrollment:

Participant gender:

Summary

This study is to evaluate whether encorafenib plus cetuximab with pembrolizumab can improve outcomes compared to pembrolizumab alone in previously untreated participants with microsatellite instability-high/ deficient mismatch repair (MSI-H/dMMR) and B-Raf proto-oncogene (BRAF V600E) mutant metastatic colorectal cancer (CRC)

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Collaborators:

Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
Merck Sharp & Dohme Corp.

Treatments:

Cetuximab
Pembrolizumab